Verona Pharma has blockbuster hopes for its recently approved drug for chronic obstructive pulmonary disorder (COPD), and preliminary sales figures for the drug suggest it is heading in the right ...

Although these products might confer significant advantages over the currently available treatments, there is still a huge unmet need for drugs that prevent the progression of COPD. Companies are ...

The US Food and Drug Administration (FDA ... as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD) in individuals with an eosinophilic phenotype.

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

Tudorza and Duaklir are inhaled respiratory drugs for chronic obstructive pulmonary disease (COPD) – and at the time of the deal Tudorza (aclidinium bromide), a long-acting muscarinic agonist ...

Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...

GSK’s GSK phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti-IL5 biologic, for treating chronic obstructive pulmonary disease (COPD), met its primary endpoint.

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing drugs, according to a new study.